Researchers at Brown University and the University of Illinois at Chicago have proposed a new framework called DASH-MC that identifies three different ways the brain can be sensitive to normal hormone changes across the menstrual cycle. Rather than viewing hormone-related mood symptoms as one single condition, the framework suggests there are at least three distinct patterns, each triggered by different hormonal events and producing different symptoms.
The first pattern involves symptoms that begin after ovulation during the luteal phase — primarily irritability, mood swings, stress sensitivity, and heightened reactions to stimuli. Evidence suggests these symptoms are caused by an abnormal brain response to rising levels of allopregnanolone, a metabolite of progesterone. This pattern aligns most closely with how PMDD is currently diagnosed. The second pattern involves depressive symptoms, cognitive difficulties, and increased suicidal thinking that begin around menstruation and can persist into the days after a period ends. Research suggests this pattern may be driven by falling or low levels of estradiol. The third pattern involves increased risky or reward-seeking behaviors — such as binge drinking or impulsive actions — around ovulation, potentially driven by estradiol surges boosting the brain's reward system.
A key insight from the paper is that hormone sensitivity is not limited to people with a PMDD diagnosis. Studies suggest that up to 60% of people with major depression and significant proportions of those with borderline personality disorder, bipolar disorder, PTSD, ADHD, and other conditions experience meaningful worsening of their symptoms at specific points in the menstrual cycle. The authors argue that recognizing these different patterns could improve diagnosis and lead to more targeted treatments — for example, distinguishing between someone whose irritability responds to SSRIs versus someone whose depression might benefit from estradiol support around menstruation. The framework is still a proposal that needs further testing, but it represents an important step toward understanding the full range of ways hormones can affect mental health.
Key findings
- Three distinct dimensions of hormone sensitivity are proposed: (1) luteal-onset symptoms driven by sensitivity to progesterone metabolite (allopregnanolone) surges, characterized by irritability and hyperarousal; (2) perimenstrual-onset symptoms driven by low or falling estradiol, characterized by depressed mood, cognitive dysfunction, and suicidality; (3) periovulatory-onset symptoms driven by estradiol surges, characterized by risky reward-seeking behaviors
- Prospectively confirmed premenstrual exacerbation (PME) appears highly prevalent in major depressive disorder, with rates as high as 60% in a large community-based study; approximately half of females with psychiatric difficulties appear to experience some form of prospectively-confirmed hormone sensitivity
- An RCT demonstrated that blocking progesterone-to-allopregnanolone metabolism using dutasteride reduces luteal symptoms in PMDD relative to placebo, supporting a causal role for allopregnanolone in luteal-onset symptoms
- Experimental studies show luteally-confined symptoms in PMDD are triggered by neural sensitivity to post-ovulatory steroid surges rather than by elevated absolute hormone levels or hormone withdrawal, as symptoms re-emerge with hormone add-back during GnRH agonist suppression but only transiently
- Crossover RCTs in transdiagnostic outpatients found that perimenstrual administration of estradiol (with or without progesterone) prevented perimenstrual worsening of suicidal ideation and depressive symptoms but did not alter premenstrual irritability, supporting distinct mechanisms for perimenstrual-onset versus luteal-onset symptoms
- In a study of PMDD symptom trajectories (N=74), 64% showed the most severe trajectory involving irritability and mood lability rising post-ovulation and continuing throughout the luteal phase
Methods, briefly
Narrative review synthesizing prospective and experimental evidence across multiple psychiatric conditions. The authors reviewed only studies using within-person prospective methods or experimental designs as primary evidence for hormone sensitivities, given the poor validity of retrospective reports. No systematic search methodology or meta-analytic procedures were described. The framework draws on RCTs (GnRH agonist studies, hormone add-back experiments, dutasteride trials, sepranolone trials, estradiol crossover trials), prospective daily diary studies, neuroimaging studies, and preclinical animal research.
Limitations to keep in mind
- This is a theoretical framework paper, not an empirical study; the proposed three dimensions require further prospective and experimental validation
- Most studies of PME in specific psychiatric disorders have small sample sizes insufficient for population-level prevalence estimates
- The periovulatory sensitivity dimension has the least empirical support and requires substantially more research
- The review primarily draws from PMDD studies, and generalizability to PME across disorders is assumed but not fully tested
- Little is known about the etiology of hormone sensitivity or whether the proposed dimensions are truly distinct versus overlapping
- No systematic review methodology was employed
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.